Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2005-03-29
2005-03-29
Caputa, Anthony C. (Department: 1646)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S387100, C530S388100, C530S388200, C530S388800, C530S389100, C530S389700, C530S391300, C530S350000, C435S007100, C435S330000, C435S331000, C435S344000, C536S023500
Reexamination Certificate
active
06872568
ABSTRACT:
The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6569642 (2003-05-01), Rauch et al.
patent: 6743625 (2004-06-01), Ni et al.
patent: 20020098550 (2002-07-01), Ni et al.
patent: 2045869 (1991-12-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 401 384 (1990-12-01), None
patent: 0 510 691 (1992-10-01), None
patent: 0 870 827 (1998-10-01), None
patent: 1 181 319 (2000-12-01), None
patent: 1 192 185 (2000-12-01), None
patent: 1 287 035 (2003-03-01), None
patent: WO 9106570 (1991-05-01), None
patent: WO 9109967 (1991-07-01), None
patent: WO 9401548 (1994-01-01), None
patent: WO 9506058 (1995-03-01), None
patent: WO 9832856 (1998-07-01), None
patent: WO 9835986 (1998-08-01), None
patent: WO 9841629 (1998-09-01), None
patent: WO 9841629 (1998-09-01), None
patent: WO 9846643 (1998-10-01), None
patent: WO 9851793 (1998-11-01), None
patent: WO 9900423 (1999-01-01), None
patent: WO 9902653 (1999-01-01), None
Bjorn, N., et al., “Fusion Proteins in biotechnology and structural biology,”Current Biol. 2:569-575 (1992).
Chinnaiyan, A.M., et al., “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95,”Science 274:990-992 (1996).
Delgado, C., et al., “The Uses and Properties of PEG-Linked Proteins,”Crit. Rev. Ther. Drug Carrier Sys. 9:249-304 (1992).
GenBank Accession No. Z66083, “H. sapiensCpG island DNA genomic Mse1 fragment,” clone 75a7, reverse read cpg75a7.rt1a, accessed Dec. 1998, Oct. 23, 1995.
GenBank Accession No. AA232440 (Feb. 28, 1997).
GenBank Accession No. AA223122 (Feb. 19, 1997).
Huston, J.S., et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,”Methods in Enzymol. 203:46-88 (1991).
Morpurgo, M., et al., “Covalent Modification of Mushroom Tyrosinase with Different Amiphiphic Polymers for Pharmaceutical and Biocatalysis Applications,”Appl. Biochem. Biotechnol. 56:59-72 (1996).
Morrison, S.L., “Transfectiomas Provide Novel Chimeric Antibodies,”Science 229:1202-1207 (1985).
Pan, G., et al., “The Receptor for the Cytotoxic Ligand TRAIL,”Science 276:111-113 (1997).
Pan, G., et al., “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL,”Science 277:815-818 (1997).
Roguska, M.A., et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,”PNAS 91:969-973 (1994).
Sheridan, J.P., et al., “Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors,”Science 277:818-821 (1997).
Wiley, et al., Identification and characterization of a new member of the TNF family that induces apoptosis,Immunity 3:673-682 (1995).
Chaudhary, P.M. et al., “Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-κB Pathway,”Immunity 7:821-830 (Dec. 1997).
Marsters, S.A. et al., “A novel receptor for APO2L/TRAIL contains a truncated death domain,”Curr. Biol. 7:1003-1006 (Dec. 1997).
Rieger, J. et al., “APO2 ligand: a novel lethal weapon against malignant glioma?”FEBS Lett. 427:124-128 (May 1998).
Schneider, P. et al., “TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF-κB,”Immunity 7:831-836 (Dec. 1997).
Sheikh, S.M. et al., “p53-dependent and -independent Regulation of the Death ReceptorKILLER/DR5Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor α,”Cancer Res. 58:1593-1598 (Apr. 1998).
Zamai, et al., “Natural killer (NK) Cell-mediated Cytotoxicity: Differential Use of TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells,”J. Exp. Med. 188:2375-2380 (Dec. 1998).
Allison, J., et al., “Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts,”Proc. Natl. Acad. Sci. USA 94:3943-3947, National Academy Press (Apr. 1997).
Allison, J., and Strasser, A., “Mechanisms of β cell death in diabetes: A minor role for CD95,”Proc. Natl. Acad. Sci. USA 95:13818-13822, National Academy Press (Nov. 1998).
Bodmer, J.-L., et al., “TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95),”Immunity 6:79-88, Cell Press (Jan. 1997).
Boldin, M.P., et al., “A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain,”J. Biol. Chem. 270:7795-7798, American Society for Biochemistry and Molecular Biology, Inc. (1995).
Chicheportiche, Y., et al., “TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis,”J. Biol. Chem. 272:32401-32410, American Society for Biochemistry and Molecular Biology, Inc. (Dec. 1997).
Chinnaiyan, A.M., et al., “FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis,”Cell 81:505-512, Cell Press (1995).
Clerici, M., et al., “Type 1 and Type 2 Cytokines in HIV Infection—A Possible Role in Apoptosis and Disease Progression,”Ann. Med. 29:185-188, Finnish Medical Society DUODECIM (Jun. 1997).
Degli-Esposti, M.A., et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family,”J. Exp. Med. 186:1165-11170, Rockefeller University Press (Oct. 1997).
Degli-Esposti, M.A., et al., “The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain,”Immunity 7:813-820, Cell Press (Dec. 1997).
Duan, H. and Dixit, V.M., “RAIDD is a new ‘death’ adaptor molecule,”Nature 385:86-89, Macmillan Publishers, Ltd. (Jan. 1997).
Frankfurt, O.S., et al., “Protection from Apoptotic Cell Death by Interleukin-4 is Increased in Previously Treated Chronic Lymphocytic Leukemia Patients,”Leuk. Res. 21:9-16, Elsevier Science, Ltd (Jan. 1997).
Gooch, J.L., et al., “Interleukin 4 Inhibits Growth and Induces Apoptosis in Human Breast Cancer Cells,”Cancer Res. 58:4199-4205, American Association for Cancer Research (Sep. 1998).
Grell, M., et al., “Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF,”EMBO J. 18:3034-3043, Oxford University Press (Jun. 1999).
Hardiman, G., et al., “Genetic Structure and Chromosomal Mapping of MyD88,”Genomics 45:332-339, Academic Press (Oct. 1997).
Hildeman, D.A., et al., “Activated T Cell Death In Vivo Mediated by Proapoptotic Bcl-2 Family Member Bim,”Immunity 16:759-767, Cell Press (Jun. 2002).
Hill, M.E., et al., “Prognostic Significance of BCL-2 Expression and b
Gentz Reiner L.
Ni Jian
Rosen Craig A.
Yu Guo-Liang
Caputa Anthony C.
Human Genome Sciences Inc.
Kaufman Claire M.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Death domain containing receptor 5 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Death domain containing receptor 5 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Death domain containing receptor 5 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3386529